Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy

References

• Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin. Infect. Dis.43(Suppl. 2), 49–56 (2006).
   PubMed Web of Science ®Google Scholar
• Grossi P, Dalla GD. Treatment of Pseudomonas aeruginosa infection in critically ill patients. Expert Rev. Anti Infect. Ther.4(4), 639–662 (2006).
   PubMedGoogle Scholar
• Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis.34(5), 634–640 (2002).
   PubMed Web of Science ®Google Scholar
• Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat. Rev. Microbiol.5(12), 939–951 (2007).
   PubMed Web of Science ®Google Scholar
• Paterson DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin. Infect. Dis.43(Suppl. 2), 43–48 (2006).
   PubMed Web of Science ®Google Scholar
• Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev.21(3), 538–582 (2008).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Rafailidis PI. Attributable mortality of Acinetobacter baumannii: no longer a controversial issue. Crit. Care11(3), 134 (2007).
   PubMed Web of Science ®Google Scholar
• Zavascki AP, Barth AL, Gonçalves AL et al. The influence of metallo-β-lactamase production on mortality in nosocomial Pseudomonas aeruginosa infections. J. Antimicrob. Chemother.58(2), 387–392 (2006).
   PubMed Web of Science ®Google Scholar
• Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis.48(1), 1–12 (2009).
   PubMed Web of Science ®Google Scholar
• Talbot GH. What is in the pipeline for Gram-negative pathogens? Expert Rev. Anti Infect. Ther.6(1), 39–49 (2008).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J. Med. Microbiol.55(Pt 12), 1619–1629 (2006).
   PubMed Web of Science ®Google Scholar
• Paterson DL, Doi Y. A step closer to extreme drug resistance (XDR) in Gram-negative bacilli. Clin. Infect. Dis.45(9), 1179–1181 (2007).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin. Infect. Dis.46(7), 1121–1122 (2008).
   PubMed Web of Science ®Google Scholar
• Livermore DM, Woodford N. The β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol.14(9), 413–420 (2006).
   PubMed Web of Science ®Google Scholar
• Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother.39(6), 1211–1233 (1995).
   PubMed Web of Science ®Google Scholar
• Ambler RP. The structure of β-lactamases. Philos. Trans. R. Soc. Lond B. Biol. Sci.289(1036), 321–331 (1980).
   PubMed Web of Science ®Google Scholar
• Jacoby GA. AmpC β-lactamases. Clin. Microbiol. Rev.22(1), 161–182 (2009).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Martinez JM, Poirel L, Nordmann P. Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. Antimicrob. Agents Chemother.53(5), 1766–1771 (2009).
   PubMed Web of Science ®Google Scholar
• Hujer KM, Hamza NS, Hujer AM et al. Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase, ADC-7 β-lactamase: defining a unique family of class C enzymes. Antimicrob. Agents Chemother.49(7), 2941–2948 (2005).
   PubMed Web of Science ®Google Scholar
• Jacobs C, Frere JM, Normark S. Cytosolic intermediates for cell wall biosynthesis and degradation control inducible β-lactam resistance in Gram-negative bacteria. Cell88(6), 823–832 (1997).
   PubMed Web of Science ®Google Scholar
• Schmidtke AJ, Hanson ND. Model system to evaluate the effect of ampD mutations on AmpC-mediated β-lactam resistance. Antimicrob. Agents Chemother.50(6), 2030–2037 (2006).
   PubMed Web of Science ®Google Scholar
• Corvec S, Caroff N, Espaze E, Giraudeau C, Drugeon H, Reynaud A. AmpC cephalosporinase hyperproduction in Acinetobacter baumannii clinical strains. J. Antimicrob. Chemother.52(4), 629–635 (2003).
   PubMed Web of Science ®Google Scholar
• Heritier C, Poirel L, Nordmann P. Cephalosporinase over-expression resulting from insertion of ISAba1 in Acinetobacter baumannii. Clin. Microbiol. Infect.12(2), 123–130 (2006).
   PubMed Web of Science ®Google Scholar
• Pai H, Jacoby GA. Sequences of the NPS-1 and TLE-1 β-lactamase genes. Antimicrob. Agents Chemother.45(10), 2947–2948 (2001).
   PubMedGoogle Scholar
• Strateva T, Yordanov D. Pseudomonas aeruginosa – a phenomenon of bacterial resistance. J. Med. Microbiol.58(Pt 9), 1133–1148 (2009).
   PubMed Web of Science ®Google Scholar
• Sanschagrin F, Bejaoui N, Levesque RC. Structure of CARB-4 and AER-1 carbenicillin-hydrolyzing β-lactamases. Antimicrob. Agents Chemother.42(8), 1966–1972 (1998).
   PubMed Web of Science ®Google Scholar
• Poirel L, Corvec S, Rapoport M et al. Identification of the novel narrow-spectrum β-lactamase SCO-1 in Acinetobacter spp. from Argentina. Antimicrob. Agents Chemother.51(6), 2179–2184 (2007).
   PubMedGoogle Scholar
• Potron A, Poirel L, Croize J, Chanteperdrix V, Nordmann P. Genetic and biochemical characterization of the first extended-spectrum CARB-type β-lactamase, RTG-4, from Acinetobacter baumannii. Antimicrob. Agents Chemother.53(7), 3010–3016 (2009).
   PubMedGoogle Scholar
• Livermore DM. Defining an extended-spectrum β-lactamase. Clin. Microbiol. Infect.14(Suppl. 1), 3–10 (2008).
   PubMedGoogle Scholar
• Weldhagen GF, Poirel L, Nordmann P. Ambler class A extended-spectrum β-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact. Antimicrob. Agents Chemother.47(8), 2385–2392 (2003).
   PubMed Web of Science ®Google Scholar
• Picao RC, Poirel L, Gales AC, Nordmann P. Further identification of CTX-M-2 extended-spectrum β-lactamase in Pseudomonas aeruginosa. Antimicrob. Agents Chemother.53(5), 2225–2226 (2009).
   PubMed Web of Science ®Google Scholar
• Moubareck C, Bremont S, Conroy MC, Courvalin P, Lambert T. GES-11, a novel integron-associated GES variant in Acinetobacter baumannii. Antimicrob. Agents Chemother.53(8), 3579–3581 (2009).
   PubMed Web of Science ®Google Scholar
• Rejiba S, Limam F, Belhadj C, Belhadj O, Ben Mahrez K. Biochemical characterization of a novel extended-spectrum β-lactamase from Pseudomonas aeruginosa. Microb. Drug Resist.8(1), 9–13 (2002).
   PubMedGoogle Scholar
• da Fonseca EL, Vieira VV, Cipriano R, Vicente AC. Emergence of blaGES-5 in clinical colistin-only-sensitive (COS) Pseudomonas aeruginosa strain in Brazil. J. Antimicrob. Chemother.59(3), 576–577 (2007).
   PubMed Web of Science ®Google Scholar
• Wang C, Cai P, Chang D, Mi Z. A Pseudomonas aeruginosa isolate producing the GES-5 extended-spectrum β-lactamase. J. Antimicrob. Chemother.57(6), 1261–1262 (2006).
   PubMed Web of Science ®Google Scholar
• Weldhagen GF, Prinsloo A. Molecular detection of GES-2 extended spectrum β-lactamase producing Pseudomonas aeruginosa in Pretoria, South Africa. Int. J. Antimicrob. Agents24(1), 35–38 (2004).
   PubMedGoogle Scholar
• Naas T, Nordmann P. OXA-type β-lactamases. Curr. Pharm. Des.5(11), 865–879 (1999).
   PubMed Web of Science ®Google Scholar
• Poirel L, Naas T, Nordmann P. Class D β-lactamases: diversity, epidemiology and genetics. Antimicrob. Agents Chemother. DOI: 10.1128/AAC.01512–01508 (2009) (Epub ahead of print).
   Google Scholar
• Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin. Microbiol. Rev.18(4), 657–686 (2005).
   PubMed Web of Science ®Google Scholar
• Juan C, Mulet X, Zamorano L, Albertí S, Pérez JL, Oliver A. Detection of the novel extended spectrum β-lactamase (ESBL) OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates in Spain. Antimicrob. Agents Chemother.53(12), 5288–5290 (2009).
   PubMed Web of Science ®Google Scholar
• Poirel L, Pitout JD, Nordmann P. Carbapenemases: molecular diversity and clinical consequences. Future Microbiol.2(5), 501–512 (2007).
   PubMed Web of Science ®Google Scholar
• Girlich D, Naas T, Nordmann P. Biochemical characterization of the naturally occurring oxacillinase OXA-50 of Pseudomonas aeruginosa. Antimicrob. Agents Chemother.48(6), 2043–2048 (2004).
   PubMed Web of Science ®Google Scholar
• Brown S, Amyes S. OXA (β)-lactamases in Acinetobacter: the story so far. J. Antimicrob. Chemother.57(1), 1–3 (2006).
   PubMed Web of Science ®Google Scholar
• Evans BA, Brown S, Hamouda A, Findlay J, Amyes SG. Eleven novel OXA-51-like enzymes from clinical isolates of Acinetobacter baumannii. Clin. Microbiol. Infect.13(11), 1137–1138 (2007).
   PubMedGoogle Scholar
• Tsakris A, Ikonomidis A, Spanakis N, Pournaras S, Bethimouti K. Identification of a novel bla(OXA-51) variant, bla(OXA-92), from a clinical isolate of Acinetobacter baumannii. Clin. Microbiol. Infect.13(3), 348–349 (2007).
   PubMedGoogle Scholar
• Vahaboglu H, Budak F, Kasap M et al. High prevalence of OXA-51-type class D β-lactamases among ceftazidime-resistant clinical isolates of Acinetobacter spp.: co-existence with OXA-58 in multiple centres. J. Antimicrob. Chemother.58(3), 537–542 (2006).
   PubMed Web of Science ®Google Scholar
• Figueiredo S, Poirel L, Croize J, Recule C, Nordmann P. In vivo selection of reduced susceptibility to carbapenems in Acinetobacter baumannii related to ISAba1-mediated overexpression of the natural bla(OXA-66) oxacillinase gene. Antimicrob. Agents Chemother.53(6), 2657–2659 (2009).
   PubMedGoogle Scholar
• Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin. Microbiol. Infect.8(6), 321–331 (2002).
   PubMed Web of Science ®Google Scholar
• Segal H, Jacobson RK, Garny S, Bamford CM, Elisha BG. Extended-10 promoter in ISAba-1 upstream of blaOXA-23 from Acinetobacter baumannii. Antimicrob. Agents Chemother.51(8), 3040–3041 (2007).
   PubMedGoogle Scholar
• Turton JF, Ward ME, Woodford N et al. The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol. Lett.258(1), 72–77 (2006).
   PubMed Web of Science ®Google Scholar
• Walsh TR. Clinically significant carbapenemases: an update. Curr. Opin. Infect. Dis.21(4), 367–371 (2008).
   PubMed Web of Science ®Google Scholar
• Poirel L, Figueiredo S, Cattoir V, Carattoli A, Nordmann P. Acinetobacter radioresistens as a silent source of carbapenem resistance for Acinetobacter spp. Antimicrob. Agents Chemother.52(4), 1252–1256 (2008).
   PubMed Web of Science ®Google Scholar
• Mendes RE, Bell JM, Turnidge JD, Castanheira M, Deshpande LM, Jones RN. Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother.53(2), 843–844 (2009).
   PubMedGoogle Scholar
• Higgins PG, Poirel L, Lehmann M, Nordmann P, Seifert H. OXA-143, a novel carbapenem-hydrolyzing Class D ss-lactamase in Acinetobacter baumannii. Antimicrob. Agents Chemother.53(12), 5035–5038 (2009).
   PubMed Web of Science ®Google Scholar
• Sevillano E, Gallego L, Garcia-Lobo JM. First detection of the OXA-40 carbapenemase in P. aeruginosa isolates, located on a plasmid also found in A. baumannii. Pathol. Biol. (Paris)57(6), 493–495 (2009).
   PubMedGoogle Scholar
• Villegas MV, Lolans K, Correa A, Kattan JN, Lopez JA, Quinn JP. First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing β-lactamase. Antimicrob. Agents Chemother.51(4), 1553–1555 (2007).
   PubMed Web of Science ®Google Scholar
• Wolter DJ, Khalaf N, Robledo IE et al. Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 β-lactamases. Antimicrob. Agents Chemother.53(4), 1660–1664 (2009).
   PubMed Web of Science ®Google Scholar
• Bennett JW, Herrera ML, Lewis JS, Wickes BW, Jorgensen JH. KPC-2-producing Enterobacter cloacae and Pseudomonas putida coinfection in a liver transplant recipient. Antimicrob. Agents Chemother.53(1), 292–294 (2009).
   PubMed Web of Science ®Google Scholar
• Yong D, Bell JM, Ritchie B, Pratt R, Toleman MA, Walsh TR. A novel sub-group metallo-β-lactamase (MBL), AIM-1, emerges in Pseudomonas aeruginosa (PSA) from Australia. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September 2007 (Abstract C1–593).
   Google Scholar
• Poirel L, Rodriguez-Martinez JM, al Naiemi N, Debets-Ossenkopp Y, Nordmann P. Characterization of blaDIM1, a novel integron-located metallo-β-lactamase gene from a Pseudomonas stutzeri clinical isolate in The Netherlands. Presented at: 19th European Congress of Clinical Microbiology and Infectious Diseases. Helsinki, Finland, 16–19 May 2009 (Abstract O309).
   Google Scholar
• Castanheira M, Toleman MA, Jones RN, Schmidt FJ, Walsh TR. Molecular characterization of a β-lactamase gene, blaGIM-1, encoding a new subclass of metallo-β-lactamase. Antimicrob. Agents Chemother.48(12), 4654–4661 (2004).
   PubMed Web of Science ®Google Scholar
• Gales AC, Menezes LC, Silbert S, Sader HS. Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM metallo-β-lactamase. J. Antimicrob. Chemother.52(4), 699–702 (2003).
   PubMed Web of Science ®Google Scholar
• Lee K, Yum JH, Yong D et al. Novel acquired metallo-β-lactamase gene, bla(SIM-1), in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea. Antimicrob. Agents Chemother.49(11), 4485–4491 (2005).
   PubMed Web of Science ®Google Scholar
• Shakil S, Khan R, Zarrilli R, Khan AU. Aminoglycosides versus bacteria – a description of the action, resistance mechanism, and nosocomial battleground. J. Biomed. Sci.15(1), 5–14 (2008).
   PubMed Web of Science ®Google Scholar
• Poole K. Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother.49(2), 479–487 (2005).
   PubMed Web of Science ®Google Scholar
• Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Aminoglycosides: activity and resistance. Antimicrob. Agents Chemother.43(4), 727–737 (1999).
   PubMed Web of Science ®Google Scholar
• Seward RJ, Lambert T, Towner KJ. Molecular epidemiology of aminoglycoside resistance in Acinetobacter spp. J. Med. Microbiol.47(5), 455–462 (1998).
   PubMedGoogle Scholar
• Nemec A, Dolzani L, Brisse S, van den Broek P, Dijkshoorn L. Diversity of aminoglycoside-resistance genes and their association with class 1 integrons among strains of pan-European Acinetobacter baumannii clones. J. Med. Microbiol.53(Pt 12), 1233–1240 (2004).
   PubMed Web of Science ®Google Scholar
• Poole K. Efflux-mediated antimicrobial resistance. J. Antimicrob. Chemother.56(1), 20–51 (2005).
   PubMed Web of Science ®Google Scholar
• Dean CR, Visalli MA, Projan SJ, Sum PE, Bradford PA. Efflux-mediated resistance to tigecycline in Pseudomonas aeruginosa PAO1. Antimicrob. Agents Chemother.47(3), 972–978 (2003).
   PubMed Web of Science ®Google Scholar
• Poole K. Efflux pumps as antimicrobial resistance mechanisms. Ann. Med.39(3), 162–176 (2007).
   PubMed Web of Science ®Google Scholar
• Piddock LJV. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin. Microbiol. Rev.19(2), 382–402 (2006).
   PubMed Web of Science ®Google Scholar
• Farra A, Islam S, Stralfors A, Sorberg M, Wretllind B. Role of outer membrane protein OprD and penicillin-binding proteins in resistance of Pseudomonas aeruginosa to imipenem and meropenem. Int. J. Antimicrob. Agents3(5), 427–433 (2008).
   Google Scholar
• Okamoto K, Gotoh N, Nishino T. Alterations of susceptibility of Pseudomonas aeruginosa by overproduction of multidrug efflux systems, MexAB-OprM, MexCD-OprJ and MexXY/OprM to carbapenems: substrate specificities of the efflux systems. J. Infect. Chemother.8(4), 371–373 (2002).
   PubMedGoogle Scholar
• Ruzin A, Keeney D, Bradford PA. AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus–Acinetobacter baumannii complex. J. Antimicrob. Chemother.59(5), 1001–1004 (2007).
   PubMed Web of Science ®Google Scholar
• Peleg AY, Adams J, Paterson DL. Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob. Agents Chemother.51(6), 2065–2069 (2007).
   PubMed Web of Science ®Google Scholar
• Marchand I, Damier-Piolle L, Courvalin P, Lambert T. Expression of the RND-type efflux pump AdeABC in Acinetobacter baumannii is regulated by the AdeRS two-component system. Antimicrob. Agents Chemother.48(9), 3298–3304 (2004).
   PubMed Web of Science ®Google Scholar
• Nemec A, Maixnerová M, van der Reijden TJK, van der Broek PJ, Dijkshoorn L. Relationship between the AdeABC efflux system gene content, netilmicin susceptibility and multidrug resistance in a genotypically diverse collection of Acinetobacter baumannii strains. J. Antimicrob. Chemother.60(3), 483–489 (2007).
   PubMedGoogle Scholar
• Damir-Piolle L, Magnet S, Brémont S, Lambert T, Courvalin P. AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii. Antimicrob. Agents Chemother.52(2), 557–562 (2008).
   PubMedGoogle Scholar
• Hancock RE, Brinkman ES. Function of pseudomonas porins in uptake and efflux Annu. Rev. Microbiol.56(1), 17–38 (2002).
   PubMed Web of Science ®Google Scholar
• Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J. Antimicrob. Chemother.47(3), 247–250 (2001).
   PubMed Web of Science ®Google Scholar
• Gotoh N, Nishino T. Decreases of the susceptibility to low molecular weight β-lactam antibiotics in imipenem-resistant Pseudomonas aeruginosa mutants: role of the outer membrane protein D2 in their diffusion. J. Antimicrob. Chemother.25(2), 191–198 (1990).
   PubMedGoogle Scholar
• Sobel ML, McKay GA, Poole K. Contribution of the MexXY multidrug transporter to aminoglycosides resistance in Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother.47(10), 3202–3207 (2003).
   PubMedGoogle Scholar
• Pai H, Kim J, Kim K, Lee JH, Choe KW, Gotoh N. Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother.45(2), 480–484 (2001).
   PubMed Web of Science ®Google Scholar
• Piddock LJV, Hall MC, Bellido F, Brains M, Hancock REW. A pleitropic posttherapy, enoxacin-resistant mutant of Pseudomonas aeruginosa. Antimicrob. Agents Chemother.36(5), 1057–1061 (1992).
   PubMedGoogle Scholar
• El Amin N, Giske CG, Jala S, Keijser B, Kronvall G, Wretlind B. Carbapenem resistance mechanisms in Pseudomonas aeruginosa alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates. APMIS113(3), 187–196 (2005).
   PubMed Web of Science ®Google Scholar
• Bratu S, Landman D, Gupta J, Quale J. Role of AmpD, OprF and penicillin-binding proteins in β-lactam resistance in clinical isolates of Pseudomonas aeruginosa. J. Med. Microbiol.56(6), 809–814 (2007).
   PubMedGoogle Scholar
• Brinkman FSL, Brains M, Hancock REW. The amino terminus of Pseudomonas aeruginosa outer membrane protein OprF forms channes in lipid bilayer membranes: correlation with a threedimensional model. J. Bacteriol.182(18), 5251–5259 (2000).
   PubMedGoogle Scholar
• Sato K, Nakae T. Outer membrane permeability of Acinetobacter calcoaceticus and its implication in antibiotic resistance. J. Antimicrob. Chemother.28(1), 35–45 (1991).
   PubMed Web of Science ®Google Scholar
• Gribun A, Nitzan Y, Pechatnikov I, Hershkovits G, Katcoff DJ. Molecular and structural characterization of the HMP-AB gene encoding a pore-forming protein from a clinical isolate of Acinetobacter baumannii. Curr. Microbiol.47(5), 434–443 (2003).
   PubMed Web of Science ®Google Scholar
• Nitzan Y, Pechatnikov I, Bar-El D, Wexler H. Isolation and characterization of heat-modifiable proteins from the outer membrane of Porphyromonas asaccharolytica and Acinetobacter baumannii. Anaerobe5(1), 43–50 (1999).
   PubMedGoogle Scholar
• Clark RB. Imipenem resistance among Acinetobacter baumannii: association with reduced expression of a 33–36 kDa outer membrane protein. J. Antimicrob. Chemother.38(2), 245–251 (1996).
   PubMed Web of Science ®Google Scholar
• Limansky AS, Mussi MA, Viale AM. Loss of a 29-kilodalton outer membrane protein in Acinetobacter baumannii is associated with imipenem resistance. J. Clin. Microbiol.40(12), 4776–4778 (2002).
   PubMedGoogle Scholar
• Mussi MA, Limansky AS, Viale AM. Acquisition of resistance to carbapenems in multidrug-resistant clinical strains of Acinetobacter baumannii: natural insertional inactivation of a gene encoding a member of a novel family of β-barrel outer membrane proteins. Antimicrob. Agents Chemother.49(4), 1432–1440 (2005).
   PubMed Web of Science ®Google Scholar
• Vila J, Martí S, Sánchez-Céspedes J. Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii. J. Antimicrob. Chemother.59(6), 1210–1215 (2007).
   PubMed Web of Science ®Google Scholar
• Quale J, Bratu S, Landman D, Heddurshetti R. Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City. Clin. Infect. Dis.37(2), 214–220 (2003).
   PubMed Web of Science ®Google Scholar
• Bou G, Cerveró G, Domínguez MA, Quereda C, Martínez-Beltrán J. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of β-lactamases. J. Clin. Microbiol.38(9), 3299–3305 (2000).
   PubMed Web of Science ®Google Scholar
• Fournier PE, Vallenet D, Barbe V et al. Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet.2(1), e7 (2006).
   PubMed Web of Science ®Google Scholar
• Li J, Nation RL, Turnidge JD et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect. Dis.6(9), 589–601 (2006).
   PubMed Web of Science ®Google Scholar
• Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY Antimicrobial Surveillance Programme (2001–2004). Clin. Microbiol. Infect.12(4), 315–321 (2006).
   PubMed Web of Science ®Google Scholar
• Park YK, Jung SI, Park KH et al. Independent emergence of colistin-resistant Acinetobacter spp. isolates from Korea. Diagn. Microbiol. Infect. Dis.64(1), 43–51 (2009).
   PubMed Web of Science ®Google Scholar
• Hogardt M, Schmoldt S, Gotzfried M, Adler K, Heesemann J. Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients. J. Antimicrob. Chemother.54(6), 1057–1061 (2004).
   PubMed Web of Science ®Google Scholar
• Landman D, Bratu S, Alam M, Quale J. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. J. Antimicrob. Chemother.55(6), 954–957 (2005).
   PubMed Web of Science ®Google Scholar
• Arroyo LA, García-Curiel A, Pachón-Ibañez ME et al. Reliability of the E-test method for detection of colistin resistance in clinical isolates of Acinetobacter baumannii. J. Clin. Microbiol.43(2), 903–905 (2005).
   PubMed Web of Science ®Google Scholar
• Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polimyxin B and colistin: review of available interpretative criteria and quality control guidelines. J. Clin. Microbiol.39(1), 183–190 (2001).
   PubMed Web of Science ®Google Scholar
• Reis AO, Luz DA, Tognim MC, Sader HS, Gales AC. Polymyxin-resistant Acinetobacter spp. isolates: what is next? Emerg. Infect. Dis.9(8), 1025–1027 (2003).
   PubMed Web of Science ®Google Scholar
• Moore RA, Chan L, Hancock RE. Evidence for two distinct mechanisms of resistance to polymyxin B in Pseudomonas aeruginosa. Antimicrob. Agents Chemother.26(4), 539–545 (1984).
   PubMed Web of Science ®Google Scholar
• Nicas TI, Hancock REW. Outer membrane protein H1 of Pseudomonas aeruginosa: involvement in adaptive and mutational resistance to ethylenediaminetetraacetate, polymyxin B, and gentamicin. J. Bacteriol.143(2), 872–878 (1980).
   PubMed Web of Science ®Google Scholar
• Bell A, Hancock RE. Outer membrane protein H1 of Pseudomonas aeruginosa: purification of the protein and cloning and nucleotide sequence of the gene. J. Bacteriol.171(6), 3211–3217 (1989).
   PubMedGoogle Scholar
• Macfarlane EL, Kwasnicka A, Hancock REW. Role of Pseudomonas aeruginosa PhoP–PhoQ in resistance to antimicrobial cationic peptides and aminoglycosides. Microbiology146(10), 2543–2554 (2000).
   PubMed Web of Science ®Google Scholar
• McPhee JB, Bains M, Winsor G et al. Contribution of the PhoP–PhoQ and PmrA–PmrB two-component regulatory systems to Mg2+-induced gene regulation in Pseudomonas aeruginosa. J. Bacteriol.188(11), 3995–4006 (2006).
   PubMed Web of Science ®Google Scholar
• Schurek KN, Sampaio JL, Kiffer CR, Sinto S, Mendes CM, Hancock RE. Involvement of pmrAB and phoPQ in polymyxin B adaptation and inducible resistance in non-cystic fibrosis clinical isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother.53(10), 4345–4351 (2009).
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for β-antimicrobial susceptibility testing: nineteenth information supplement (M100-S19), CLSI, Wayne, PA, USA (2009).
   Google Scholar
• Hawley JS, Murray CK, Jorgensen JH. Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy. Antimicrob. Agents Chemother.52(1), 351–352 (2008).
   PubMed Web of Science ®Google Scholar
• Ko KS, Suh JY, Kwon KT et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J. Antimicrob. Chemother.60(5), 1163–1167 (2007).
   PubMed Web of Science ®Google Scholar
• Megerle JA, Fritz G, Gerland U, Jung K, Radler JO. Timing and dynamics of single cell gene expression in the arabinose utilization system. Biophys. J.95(4), 2103–2115 (2008).
   PubMedGoogle Scholar
• Booth IR. Stress and the single cell: intrapopulation diversity is a mechanism to ensure survival upon exposure to stress. Int. J. Food Microbiol.78(1–2), 19–30 (2002).
   PubMed Web of Science ®Google Scholar
• Adams MD, Nickel GC, Bajaksouzian S et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob. Agents Chemother.53(9), 3628–3634 (2009).
   PubMed Web of Science ®Google Scholar
• Avery SV. Microbial cell individuality and the underlying sources of heterogeneity. Nat. Rev. Microbiol.4(8), 577–587 (2006).
   PubMed Web of Science ®Google Scholar
• Li J, Nation RL, Owen RJ, Wong S, Spelman D, Franklin C. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin. Infect. Dis.45(5), 594–598 (2007).
   PubMed Web of Science ®Google Scholar
• Mendes RE, Fritsche TR, Sader HS, Jones RN. Increased antimicrobial susceptibility profiles among polymyxin-resistant Acinetobacter baumannii clinical isolates. Clin. Infect. Dis.46(8), 1324–1326 (2008).
   PubMed Web of Science ®Google Scholar
• Noguchi H, Fukasawa M, Komatsu T, Mitsuhashi S, Matsuhashi M. Mutation in Pseudomonas aeruginosa causing simultaneous defects in penicillin-binding protein 5 and in enzyme activities of penicillin release and D-alanine carboxypeptidase. J. Bacteriol.162(2), 849–851 (1985).
   PubMedGoogle Scholar
• Pucci MJ, Boice-Sowek J, Kessker RE, Dougherty TJ. Comparison of cefepime, cefpirome and cefaclidine binding affinities for penicillin-binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC8329. Antimicrob. Agents Chemother.35(11), 2312–2317 (1991).
   PubMed Web of Science ®Google Scholar
• Quinn JP, Dudek EJ, DiVincenzo CA, Lucks DA, Lerner SA. Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J. Infect. Dis.154(2), 289–294 (1986).
   PubMed Web of Science ®Google Scholar
• Song J, Xie G, Elf PK, Young KD, Jensen RA. Comparative analysis of Pseudomonas aeruginosa penicillin-binding protein 7 in the context of its membership in the family of low-molecular-mass PBPs. Microbiology144(4), 975–983 (1998).
   PubMedGoogle Scholar
• Legaree BA, Daniels K, Weadge JT, Cockburn D, Clarke AJ. Function of penicillin-binding protein 2 in viability and morphology of Pseudomonas aeruginosa. J. Antimicrob. Chemother.59(3), 411–424 (2007).
   PubMedGoogle Scholar
• Godfrey AJ, Bryan LE, Rabin HR. β-lactam-resistant Pseudomonas aeruginosa with modified penicillin-binding proteins emerging during cystic fibrosis treatment. Antimicrob. Agents Chemother.19(5), 705–711 (1981).
   PubMed Web of Science ®Google Scholar
• Gehrlein M, Leying H, Cullmann W, Wendt S, Opferkuch W. Imipenem resistance in Acinetobacter baumannii is due to altered penicillin-binding proteins. Chemotherapy37(6), 405–412 (1991).
   PubMed Web of Science ®Google Scholar
• Fernández-Cuenca F, Pascual A, Martínez Marínez L, Conejo MC, Perea EJ. Evaluation of SDS-polyacrylamide gel systems for the study of outer membrane protein profiles of clinical strains of Acinetobacter baumannii. J. Basic Microbiol.43(3), 194–201 (2003).
   PubMedGoogle Scholar
• Russo TA, MacDonald U, Beanan JM et al. Penicillin-binding protein 7/8 contributes to the survival of Acinetobacter baumanniiin vitro and in vivo. J. Infect. Dis.199(4), 513–521 (2009).
   PubMed Web of Science ®Google Scholar
• Higgins PG, Wisplinghoff H, Stefanik D, Seifert H. Selection of topoisomerase mutations and overexpression of adeB mRNA transcripts during an outbreak of Acinetobacter baumannii. J. Antimicrob. Chemother.54(4), 821–823 (2004).
   PubMedGoogle Scholar
• Hamouda A, Amyes SG. Novel gyrA and parC point mutations in two strains of Acinetobacter baumannii resistant to ciprofloxacin. J. Antimicrob. Chemother.54(3), 695–696 (2004).
   PubMedGoogle Scholar
• Nakano M, Deguchi T, Wamura T et al. Mutations in the gyrA and parC genes in fluoroquinolone-resistant clinical isolates of Pseudomonas aeruginosa. Antimicrobial. Agents Chemother.41(10), 2289–2291 (1997).
   PubMed Web of Science ®Google Scholar
• Seward RJ, Towner KJ. Molecular epidemiology of quinolone resistance in Acinetobacter spp. Clin. Microbiol. Infect.4(5), 248–254 (1998).
   PubMedGoogle Scholar
• Su XZ, Chen J, Mizushima T, Kuroda T, Tsuchiya T. AbeM, an H+-coupled Acinetobacter baumannii multidrug efflux pump belonging to the MATE family of transporters. Antimicrob. Agents Chemother.49(10), 4362–4364 (2005).
   PubMedGoogle Scholar
• Touati A, Brasme L, Benallaoua S, Gharout A, Madoux J, De Champs C. First report of qnrB-producing Enterobacter cloacae and qnrA-producing Acinetobacter baumannii recovered from Algerian hospitals. Diagn. Microbiol. Infect. Dis.60(3), 287–290 (2008).
   PubMed Web of Science ®Google Scholar
• Jana S, Deb JK. Molecular understanding of aminoglycoside action and resistance. Appl. Microbiol. Biotechnol.70(2), 140–150 (2006).
   PubMed Web of Science ®Google Scholar
• Doi Y, Arakawa Y. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. Clin. Infect. Dis.45(1), 88–94 (2007).
   PubMed Web of Science ®Google Scholar
• Zavascki AP, Li J. Intravenous colistimethate for multidrug-resistant Gram-negative bacteria. Lancet Infect. Dis.8(7), 403–405 (2008).
   PubMed Web of Science ®Google Scholar
• Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J. Antimicrob. Chemother.60(6), 1206–1215 (2007).
   PubMed Web of Science ®Google Scholar
• Schafer JJ, Goff DA. Establishing the role of tigecycline in an era of antimicrobial resistance. Expert Rev. Anti Infect. Ther.6(5), 557–567 (2008).
   PubMed Web of Science ®Google Scholar
• Masterton RG. The new treatment paradigm and the role of carbapenems. Int. J. Antimicrob. Agents33(2), 105–110 (2009).
   PubMedGoogle Scholar
• Queenan AM, Bush K. Carbapenemases: the versatile β-lactamases. Clin. Microbiol. Rev.20(3), 440–458 (2007).
   PubMed Web of Science ®Google Scholar
• Turnidge J, Paterson DL. Setting and revising antibacterial susceptibility breakpoints. Clin. Microbiol. Rev.20(3), 391–408 (2007).
   PubMed Web of Science ®Google Scholar
• Dalhoff A, Ambrose PG, Mouton JW. A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints. Infection37(4), 296–305 (2009).
   PubMed Web of Science ®Google Scholar
• Cornaglia G, Akova M, Amicosante G et al. Metallo-β-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. Int. J. Antimicrob. Agents29(4), 380–388 (2007).
   PubMed Web of Science ®Google Scholar
• Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. Clin. Microbiol. Rev.21(3), 449–465 (2008).
   PubMed Web of Science ®Google Scholar
• Li J, Coulthard K, Milne R et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J. Antimicrob. Chemother.52(6), 987–992 (2003).
   PubMed Web of Science ®Google Scholar
• Li J, Rayner CR, Nation RL et al. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob. Agents Chemother.49(11), 4814–4815 (2005).
   PubMed Web of Science ®Google Scholar
• Kwa AL, Lim TP, Low JG et al. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn. Microbiol. Infect. Dis.60(2), 163–167 (2008).
   PubMed Web of Science ®Google Scholar
• Zavascki AP, Goldani LZ, Cao G et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin. Infect. Dis.47(10), 1298–1304 (2008).
   PubMed Web of Science ®Google Scholar
• Plachouras D, Karvanen M, Friberg LE et al. Population pharmacokinetic analysis of colistin methanesulphonate and colistin after intravenous administration in critically ill patients with Gram-negative bacterial infections. Antimicrob. Agents Chemother.53(8), 3430–3436 (2009).
   PubMed Web of Science ®Google Scholar
• Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother.45(3), 781–785 (2001).
   PubMed Web of Science ®Google Scholar
• Tam VH, Schilling AN, Vo G et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob. Agents Chemother.49(9), 3624–3630 (2005).
   PubMed Web of Science ®Google Scholar
• Owen RJ, Li J, Nation RL, Spelman D. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J. Antimicrob. Chemother.59(3), 473–477 (2007).
   PubMed Web of Science ®Google Scholar
• Li J, Rayner CR, Nation RL et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother.50(9), 2946–2950 (2006).
   PubMed Web of Science ®Google Scholar
• Tan CH, Li J, Nation RL. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob. Agents Chemother.51(9), 3413–3415 (2007).
   PubMed Web of Science ®Google Scholar
• Zavascki AP, Li J, Nation RL et al. Stable polymyxin B susceptibility to Pseudomonas aeruginosa and Acinetobacter spp. despite persistent recovery of these organisms from respiratory secretions of patients with ventilator-associated pneumonia treated with this drug. J. Clin. Microbiol.47(9), 3064–3065 (2009).
   PubMedGoogle Scholar
• Bergen PJ, Li J, Nation RL, Turnidge JD, Coulthard K, Milne RW. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J. Antimicrob. Chemother.61(3), 636–642 (2008).
   PubMed Web of Science ®Google Scholar
• Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J. Antimicrob. Chemother.53(5), 837–840 (2004).
   PubMed Web of Science ®Google Scholar
• Cirioni O, Ghiselli R, Orlando F et al. Efficacy of colistin/rifampin combination in experimental rat models of sepsis due to a multiresistant Pseudomonas aeruginosa strain. Crit. Care Med.35(7), 1717–1723 (2007).
   PubMed Web of Science ®Google Scholar
• Giamarellou H. Treatment options for multidrug-resistant bacteria. Expert Rev. Anti Infect. Ther.4(4), 601–618 (2006).
   PubMedGoogle Scholar
• Peterson LR. A review of tigecycline – the first glycylcycline. Int. J. Antimicrob. Agents32(Suppl. 4), 215–222 (2008).
   PubMed Web of Science ®Google Scholar
• Gordon NC, Wareham DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J. Antimicrob. Chemother.63(4), 775–780 (2009).
   PubMed Web of Science ®Google Scholar
• Vasilev K, Reshedko G, Orasan R et al. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J. Antimicrob. Chemother.62(Suppl. 1), 29–40 (2008).
   PubMed Web of Science ®Google Scholar
• Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J. Antimicrob. Chemother.62(1), 45–55 (2008).
   PubMed Web of Science ®Google Scholar
• Rahal JJ. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin. Infect. Dis.43(Suppl. 2), S95–S99 (2006).
   PubMed Web of Science ®Google Scholar
• Casal M, Rodríguez F, Johnson B et al. Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible Acinetobacter spp. J. Antimicrob. Chemother.64(1), 69–72 (2009).
   PubMed Web of Science ®Google Scholar
• Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J. Antimicrob. Chemother.59(4), 772–774 (2007).
   PubMed Web of Science ®Google Scholar
• Canigia LF, Bantar C. Susceptibility testing of tigecycline against Acinetobacter spp. by disc diffusion method: withdrawing a therapeutic option by varying the Mueller–Hinton agar? J. Antimicrob. Chemother.62(6), 1463–1464 (2008).
   PubMedGoogle Scholar
• Petersen PJ, Bradford PA. Effect of medium age and Supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates. Antimicrob. Agents Chemother.49(9), 3910–3918 (2005).
   PubMed Web of Science ®Google Scholar
• Hope R, Warner M, Mushtaq S, Ward ME, Parsons T, Livermore DM. Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines. J. Antimicrob. Chemother.56(6), 1042–1046 (2005).
   PubMed Web of Science ®Google Scholar
• Bradford PA, Petersen PJ, Young M, Jones CH, Tischler M, O’Connell J. Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method. Antimicrob. Agents Chemother.49(9), 3903–3909 (2005).
   PubMed Web of Science ®Google Scholar
• Fernández-Mazarrasa C, Mazarrasa O, Calvo J et al. High concentrations of manganese in Mueller–Hinton agar increase MICs of tigecycline determined by Etest. J. Clin. Microbiol.47(3), 827–829 (2009).
   PubMed Web of Science ®Google Scholar
• MacGowan AP. Tigecycline pharmacokinetic/pharmacodynamic update. J. Antimicrob. Chemother.62(Suppl. 1), 11–16 (2008).
   PubMed Web of Science ®Google Scholar
• Peleg AY, Potoski BA, Rea R et al.Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J. Antimicrob. Chemother.59(1), 128–131 (2007).
   PubMed Web of Science ®Google Scholar
• Burkhardt O, Rauch K, Kaever V, Hadem J, Kielstein JT, Welte T. Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int. J. Antimicrob. Agents34(1), 101–102 (2009).
   PubMed Web of Science ®Google Scholar
• Conte JE Jr, Golden JA, Kelly MG, Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int. J. Antimicrob. Agents25(6), 523–529 (2005).
   PubMed Web of Science ®Google Scholar
• Tanaseanu C, Bergallo C, Teglia O et al. Integrated results of 2 Phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn. Microbiol. Infect. Dis.61(3), 329–338 (2008).
   PubMed Web of Science ®Google Scholar
• Bergallo C, Jasovich A, Teglia O et al. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized Phase 3 comparison study with levofloxacin. Diagn. Microbiol. Infect. Dis.63(1), 52–61 (2009).
   PubMed Web of Science ®Google Scholar
• Curcio D. Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective. J. Clin. Microbiol.46(5), 1892–1893 (2008).
   PubMed Web of Science ®Google Scholar
• Cunha BA. Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis. J. Clin. Microbiol.47(5), 1613 (2009).
   PubMed Web of Science ®Google Scholar
• Endimiani A, Perez F, Bonomo RA. Cefepime: a reappraisal in an era of increasing antimicrobial resistance. Expert Rev. Anti Infect. Ther.6(6), 805–824 (2008).
   PubMed Web of Science ®Google Scholar
• Bhat SV, Peleg AY, Lodise TP Jr et al. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by Gram-negative organisms. Antimicrob. Agents Chemother.51(12), 4390–4395 (2007).
   PubMed Web of Science ®Google Scholar
• Gin A, Dilay L, Karlowsky JA, Walkty A, Rubinstein E, Zhanel GG. Piperacillin-tazobactam: a β-lactam/β-lactamase inhibitor combination. Expert Rev. Anti Infect. Ther.5(3), 365–383 (2007).
   PubMed Web of Science ®Google Scholar
• Tam VH, Gamez EA, Weston JS et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin–tazobactam: implications on the appropriateness of the resistance breakpoint. Clin. Infect. Dis.46(6), 862–867 (2008).
   PubMed Web of Science ®Google Scholar
• Zavascki AP, Barth AL, Goldani LZ. Nosocomial bloodstream infections due to metallo-β-lactamase-producing Pseudomonas aeruginosa. J. Antimicrob. Chemother.61(5), 1183–1185 (2008).
   PubMedGoogle Scholar
• Sader HS, Jones RN. Comprehensive in vitro evaluation of cefepime combined with aztreonam or ampicillin/sulbactam against multi-drug resistant Pseudomonas aeruginosa and Acinetobacter spp. Int. J. Antimicrob. Agents25(5), 380–384 (2005).
   PubMed Web of Science ®Google Scholar
• Vinks AA, van Rossem RN, Mathôt RA, Heijerman HG, Mouton JW. Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose–exposure relationships using Monte Carlo simulation. Antimicrob. Agents Chemother.51(9), 3049–3055 (2007).
   PubMed Web of Science ®Google Scholar
• Vidal L, Gafter-Gvili A, Borok S, Fraser A, Leibovici L, Paul M. Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. J. Antimicrob. Chemother.60(2), 247–257 (2007).
   PubMed Web of Science ®Google Scholar
• Leibovici L, Paul M, Poznanski O et al. Monotherapy versus β-lactam-aminoglycoside combination treatment for Gram-negative bacteremia: a prospective, observational study. Antimicrob. Agents Chemother.41(5), 1127–1133 (1997).
   PubMed Web of Science ®Google Scholar
• Lacy MK, Nicolau DP, Nightingale CH, Quintiliani R. The pharmacodynamics of aminoglycosides. Clin. Infect. Dis.27(1), 23–27 (1998).
   PubMed Web of Science ®Google Scholar
• Lode HM. Rational antibiotic therapy and the position of ampicillin/sulbactam. Int. J. Antimicrob. Agents32(1), 10–28 (2008).
   PubMed Web of Science ®Google Scholar
• Akova M. Sulbactam-containing β-lactamase inhibitor combinations. Clin. Microbiol. Infect.14(Suppl. 1), 185–188 (2008).
   PubMedGoogle Scholar
• Rafailidis PI, Ioannidou EN, Falagas ME. Ampicillin/sulbactam: current status in severe bacterial infections. Drugs67(13), 1829–1849 (2007).
   PubMed Web of Science ®Google Scholar
• Swenson JM, Killgore GE, Tenover FC. Antimicrobial susceptibility testing of Acinetobacter spp. by NCCLS broth microdilution and disk diffusion methods. J. Clin. Microbiol.42(11), 5102–5108 (2004).
   PubMedGoogle Scholar
• Paul M, Leibovici L. Combination antimicrobial treatment versus monotherapy: the contribution of meta-analyses. Infect. Dis. Clin. North Am.23(2), 277–293 (2009).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Rafailidis PI, Matthaiou DK, Virtzili S, Nikita D, Michalopoulos A. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int. J. Antimicrob. Agents32(5), 450–454 (2008).
   PubMed Web of Science ®Google Scholar
• Kalai BS, Achour W, Bejaoui M, Abdeladhim A, Ben Hassen A. Detection of SHV-1 β-lactamase in Pseudomonas aeruginosa strains by genetic methods. Pathol. Biol. (Paris)57(3), e73–e75 (2009).
   Google Scholar
• Celenza G, Pellegrini C, Caccamo M, Segatore B, Amicosante G, Perilli M. Spread of bla(CTX-M-type) and bla(PER-2) β-lactamase genes in clinical isolates from Bolivian hospitals. J. Antimicrob. Chemother.57(5), 975–978 (2006).
   PubMed Web of Science ®Google Scholar
• Jiang X, Zhang Z, Li M, Zhou D, Ruan F, Lu Y. Detection of extended-spectrum β-lactamases in clinical isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother.50(9), 2990–2995 (2006).
   PubMed Web of Science ®Google Scholar
• al Naiemi N, Duim B, Bart A. A CTX-M extended-spectrum β-lactamase in Pseudomonas aeruginosa and Stenotrophomonas maltophilia. J. Med. Microbiol.55(11), 1607–1608 (2006).
   PubMed Web of Science ®Google Scholar
• Giuliani F, Docquier JD, Riccio ML, Pagani L, Rossolini GM. OXA-46, a new class D β-lactamase of narrow substrate specificity encoded by a blaVIM-1-containing integron from a Pseudomonas aeruginosa clinical isolate. Antimicrob. Agents Chemother.49(5), 1973–1980 (2005).
   PubMed Web of Science ®Google Scholar
• Bert F, Vanjak D, Leflon-Guibout V et al. IMP-4-producing Pseudomonas aeruginosa in a French patient repatriated from Malaysia: impact of early detection and control measures. Clin. Infect. Dis.44(5), 764–765 (2007).
   PubMedGoogle Scholar
• Ryoo NH, Lee K, Lim JB, Lee YH, Bae IK, Jeong SH. Outbreak by meropenem-resistant Pseudomonas aeruginosa producing IMP-6 metallo-β-lactamase in a Korean hospital. Diagn. Microbiol. Infect. Dis.63(1), 115–117 (2009).
   PubMed Web of Science ®Google Scholar
• Iyobe S, Kusadokoro H, Takahashi A et al. Detection of a variant metallo-β-lactamase, IMP-10, from two unrelated strains of Pseudomonas aeruginosa and an Alcaligenes xylosoxidans strain. Antimicrob. Agents Chemother.46(6), 2014–2016 (2002).
   PubMed Web of Science ®Google Scholar
• Docquier JD, Riccio ML, Mugnaioli C et al. IMP-12, a new plasmid-encoded metallo-β-lactamase from a Pseudomonas putida clinical isolate. Antimicrob. Agents Chemother.47(5), 1522–1528 (2003).
   PubMed Web of Science ®Google Scholar
• Garza-Ramos U, Morfin-Otero R, Sader HS et al. Metallo-β-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico. Antimicrob. Agents Chemother.52(8), 2943–2946 (2008).
   PubMed Web of Science ®Google Scholar
• Mendes RE, Toleman MA, Ribeiro J, Sader HS, Jones RN, Walsh TR. Integron carrying a novel metallo-β-lactamase gene, blaIMP-16, and a fused form of aminoglycoside-resistant gene aac(6’)-30/aac(6’)-Ib’: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother.48(12), 4693–4702 (2004).
   PubMed Web of Science ®Google Scholar
• Duljasz W, Gniadkowski M, Sitter S, Wojna A, Jebelean C. First organisms with acquired metallo-β-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria. Antimicrob. Agents Chemother.53(5), 2221–2222 (2009).
   PubMed Web of Science ®Google Scholar
• Koh TH, Wang GC, Sng LH. IMP-1 and a novel metallo-β-lactamase, VIM-6, in fluorescent Pseudomonads isolated in Singapore. Antimicrob. Agents Chemother.48(6), 2334–2336 (2004).
   PubMed Web of Science ®Google Scholar
• Siarkou VI, Vitti D, Protonotariou E, Ikonomidis A, Sofianou D. Molecular epidemiology of outbreak-related Pseudomonas aeruginosa strains carrying the novel variant blaVIM-17 metallo-β-lactamase gene. Antimicrob. Agents Chemother.53(4), 1325–1330 (2009).
   PubMed Web of Science ®Google Scholar
• Castanheira M, Bell JM, Turnidge JD, Mathai D, Jones RN. Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-β-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18). Antimicrob. Agents Chemother.53(3), 1225–1227 (2009).
   PubMed Web of Science ®Google Scholar
• Toleman MA, Simm AM, Murphy TA et al. Molecular characterization of SPM-1, a novel metallo-β-lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme. J. Antimicrob. Chemother.50(5), 673–679 (2002).
   PubMed Web of Science ®Google Scholar
• Hujer KM, Hamza NS, Hujer AM et al. Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase, ADC-7 β-lactamase: defining a unique family of class C enzymes. Antimicrob. Agents Chemother.49(7), 2941–2848 (2005).
   PubMed Web of Science ®Google Scholar
• Pasteran F, Rapoport M, Petroni A et al. Emergence of PER-2 and VEB-1a in Acinetobacter baumannii strains in the Americas. Antimicrob. Agents Chemother.50(9), 3222–3224 (2006).
   PubMedGoogle Scholar
• Poirel L, Menuteau O, Agoli N, Cattoen C, Nordmann P. Outbreak of extended-spectrum β-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a French hospital. J. Clin. Microbiol.41(8), 3542–3547 (2003).
   PubMed Web of Science ®Google Scholar
• Huang LY, Chen TL, Lu PL et al. Dissemination of multidrug-resistant, class 1 integron-carrying Acinetobacter baumannii isolates in Taiwan. Clin. Microbiol. Infect.14(11), 1010–1019 (2008).
   PubMed Web of Science ®Google Scholar
• Naiemi NA, Duim B, Savelkoul PH et al. Widespread transfer of resistance genes between bacterial species in an intensive care unit: implications for hospital epidemiology. J. Clin. Microbiol.43(9), 4862–4864 (2005).
   PubMed Web of Science ®Google Scholar
• Nagano N, Nagano Y, Cordevant C, Shibata N, Arakawa Y. Nosocomial transmission of CTX-M-2 β-lactamase-producing Acinetobacter baumannii in a neurosurgery ward. J. Clin. Microbiol.42(9), 3978–3984 (2004).
   PubMed Web of Science ®Google Scholar
• Choury D, Szajnert MF, Joly-Guillou ML, Azibi K, Delpech M, Paul G. Nucleotide sequence of the bla(RTG-2) (CARB-5) gene and phylogeny of a new group of carbenicillinases. Antimicrob. Agents Chemother.44(4), 1070–1074 (2000).
   PubMedGoogle Scholar
• Mammeri H, Poirel L, Mangeney N, Nordmann P. Chromosomal integration of a cephalosporinase gene from Acinetobacter baumannii into Oligella urethralis as a source of acquired resistance to β-lactams. Antimicrob. Agents Chemother.47(5), 1536–1542 (2003).
   PubMedGoogle Scholar
• Sung JY, Kwon KC, Park JW et al. Dissemination of IMP-1 and OXA type β-lactamase in carbapenem-resistant Acinetobacter baumannii. Korean J. Lab. Med.28(1), 16–23 (2008).
   PubMedGoogle Scholar
• Giordano A, Varesi P, Bertini A et al. Outbreak of Acinetobacter baumannii producing the carbapenem-hydrolyzing oxacillinase OXA-58 in Rome, Italy. Microb. Drug Resist.13(1), 37–43 (2007).
   PubMedGoogle Scholar
• Wang H, Guo P, Sun H et al. Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. Antimicrob. Agents Chemother.51(11), 4022–4028 (2007).
   PubMed Web of Science ®Google Scholar
• Tsakris A, Ikonomidis A, Pournaras S et al. VIM-1 metallo-β-lactamase in Acinetobacter baumannii. Emerg. Infect. Dis.12(6), 981–983 (2006).
   PubMed Web of Science ®Google Scholar
• Yum JH, Yi K, Lee H et al. Molecular characterization of metallo-β-lactamase-producing Acinetobacter baumannii and Acinetobacter genomospecies 3 from Korea: identification of two new integrons carrying the bla(VIM-2) gene cassettes. J. Antimicrob. Chemother.49(5), 837–840 (2002).
   PubMedGoogle Scholar
• Lee MF, Peng CF, Hsu HJ, Chen YH. Molecular characterisation of the metallo-β-lactamase genes in imipenem-resistant Gram-negative bacteria from a university hospital in southern Taiwan. Int. J. Antimicrob. Agents32(6), 475–480 (2008).
   PubMed Web of Science ®Google Scholar
• Figueiredo S, Poirel L, Papa A, Koulourida V, Nordmann P. First identification of VIM-4 metallo-β-lactamase in Acinetobacter spp. Clin. Microbiol. Infect.14(3), 289–290 (2008).
   PubMedGoogle Scholar
• Kohler T, Van Delden C, Curty LK et al. Overexpression of the MexEF-OprN multidrug efflux system affects cell-to-cell signaling in Pseudomonas aeruginosa. J. Bacteriol.183(18), 5213–5222 (2001).
   PubMed Web of Science ®Google Scholar
• Westbrock-Wadman S, Sherman DR, Hickey MJ et al. Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability. Antimicrob. Agents Chemother.43(12), 2975–2983 (2004).
   Google Scholar
• Pozzi G, Iannelli F, Oggioni MR et al. Genetic elements carrying macrolide-efflux genes in streptococci. Curr. Drug Targets Infect. Disord.4(3), 203–206 (2004).
   PubMedGoogle Scholar
• Li XZ, Poole K, Nikaido H. Contributions of MexAB-OprM and an ErmE homolog to intrinsic resistance of Pseudomonas aeruginosa to aminoglycosides and dyes. Antimicrob. Agents Chemother.47(1), 27–33 (2003).
   PubMed Web of Science ®Google Scholar
• Magnet S, Courvalin P, Lambert T. Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrob. Agents Chemother.45(12), 3375–3380 (2001).
   PubMed Web of Science ®Google Scholar
• Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother.44(12), 3322–3327 (2000).
   PubMed Web of Science ®Google Scholar
• Masuda N, Sakagawa E, Ohya S. Outer membrane proteins responsible for multiple drug resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother.39(3), 645–649 (1995).
   PubMed Web of Science ®Google Scholar
• Gotoh N, Tsujimoto H, Nomura A, Okamoto K, Tsuda M, Nishino T. Functional replacement of OprJ by OprM in the MexCD–OprJ multidrug efflux system of Pseudomonas aeruginosa. FEMS Microbiol. Lett.165(1), 21–27 (1998).
   PubMed Web of Science ®Google Scholar
• Zhao Q, Li XZ, Mistry A et al. Influence of the TonB energy-coupling protein on efflux-mediated multidrug resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother.42(9), 2225–2231 (1998).
   PubMed Web of Science ®Google Scholar
• Poole K, Zhao Q, Neshat S, Heinrichs DE, Dean CR. The Pseudomonas aeruginosatonB gene encodes a novel TonB protein. Microbiology142(Pt 6), 1449–1458 (1996).
   PubMedGoogle Scholar
• Dupont M, Pagès JM, Lafitte D, Siroy A, Bollet C. Identification of an OprD homologue in Acinetobacter baumannii. J. Proteome Res.4(6), 2386–2390 (2005).
   PubMed Web of Science ®Google Scholar
• Jaruratanasirikul S, Sudsai T. Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion. J. Antimicrob. Chemother.63(3), 560–563 (2009).
   PubMedGoogle Scholar
• Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J. Antimicrob. Chemother.64(1), 142–150 (2009).
   PubMed Web of Science ®Google Scholar
• Nicasio AM, Ariano RE, Zelenitsky AS et al. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob. Agents Chemother.53(4), 1476–1481 (2009).
   PubMed Web of Science ®Google Scholar
• Roos JF, Bulitta J, Lipman J, Kirkpatrick CM. Pharmacokinetic–pharmacodynamic rationale for cefepime dosing regimens in intensive care units. J. Antimicrob. Chemother.58(5), 987–993 (2006).
   PubMed Web of Science ®Google Scholar
• Kim A, Sutherland CA, Kuti JL, Nicolau DP. Optimal dosing of piperacillin–tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion? Pharmacotherapy27(11), 1490–1497 (2007).
   PubMed Web of Science ®Google Scholar